Dx M&A Market Remains Stagnant in H1 2024
Macroeconomic uncertainty, confusion surrounding the diagnostic regulatory landscape, and the continuing post-COVID-19 pandemic hangover have all contributed to a stagnant, quiet period for mergers and acquisitions in the in vitro diagnostics space in the first half of 2024.
News
Outcome Capital Launches Pharmacy and Related Services Advisory Board to Advance Innovation Across the Healthcare Sector
Thom Stambaugh, recognized leader in pharmacy innovation and care delivery transformation, will serve as inaugural member Boston, MA – November 12, 2025 — Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced the formation of its Pharmacy and Related Services Advisory Board, a new initiative within the […]
Read MoreResources
Outcome Capital Life Science Market Pulse, September 2025
Outcome Capital Life Science Market Pulse September 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
